Alzheimer Immunotherapy,Team Lead, Primary Care Business Unit, Clinical SciencesDirected all clinical development activities in multi-compound, multi-study development program on Wyeth/Pfizer side of alliance with Elan Pharmaceuticals/Janssen; including two worldwide (27 countries) bapineuzumab phase 3 trials, phase 2 study of ACC-001, phase 1 study of bapineuzumab, and early clinical development of follow-on compounds. Continued leadership of group after Pfizer acquisition of Wyeth in October 2009.

Alzheimer Immunotherapy Program Clinical Team Lead, Neuroscience Therapeutic Area, Wyeth Research. Headed all clinical development activities in multi-compound, multi-study development program on Wyeth side of research and development alliance with Elan, including monoclonal antibody AAB-001, and active immunization ACC-001, phase 1 – 3. Managed up to ten direct reports, including three physicians (two neurologists, one psychiatrist). Hiring manager for most direct reports, including six recruited from outside Wyeth Served on key cross alliance governance committees and internal leadership teams

Clinical project team leader, Alzheimer Immunotherapy Program, led multicompound, multistudy program on Wyeth side of Wyeth Elan partnership.Clinical team leader, multistudy, international phase 2 development program of lecozotan for symptomatic treatment of ADClinical team leader, phase 1 compounds for AD including multiple IND filings.Clinical team leader, phase 2 development program of compound for treatment of multiple sclerosisIn-licensing activities – Participated in confidential evaluation and due diligence of multiple in-licensing candidates in AD and other CNS disorders.

Co-clinical lead of international phase 2A proof-of-concept study with AN1792, with clinical, imaging, immunologic, CSF biomarker, and pharmacogenomic endpoints. Clinical Project Team Leader, Effexor New Indications program (social anxiety disorder and panic disorder)Designed, initiated and executed international registration program (6 studies) for Effexor in social anxiety disorder, including design and execution of successful pediatric study, leading to NDA and successful registration in indication.Co-led single non-registration study in panic disorder.Clinical Project Team Leader, Phase 3 Alzheimer development program for estrogen compounds in AD (discontinued). Clinical Project Team Leader, phase 0 development program for symptomatic treatment of ADMedical monitor, phase 0 - 2 development program in epilepsy (2 compounds)Worked on protocols, monitoring and data review, IND and other regulatory submissions.

Phase 2 acute stroke programDeveloped protocol, monitored investigational sites and conduct of ongoing studies, established AE reporting system, reviewed preliminary data.Medical monitor, Phase 3 hypnotic programMonitored investigational sites and ongoing study conduct. Performed DPR review and worked to formulate IND updates and pre-NDA format package, assisted with successful NDA submission

Conducted laboratory research in AD, including as PI under own NIA Clinical Investigator AwardDirected subspecialty clinic for evaluation of patients with memory disorders at Burke Rehabilitation Hospital Supervised residents on Neurology Services of New York HospitalLecturer, second -year Neurology course at Cornell Medical CollegeInvestigator in numerous industry and NIA-sponsored clinical trials for treatment of AD and other dementias.